
Liquid Biopsy Enables Precision Cancer Care: Bill Morice, M.D., Ph.D.
4/3/2025
0:00
11:09
In this episode of “Answers From the Lab,” William Morice II, M.D., Ph.D., CEO and president of Mayo Clinic Laboratories, invited Min-Han Tan, M.B.B.S., FRCP, Ph.D., founding CEO and medical director of Lucence, to discuss liquid biopsy cancer testing. Mayo Clinic Laboratories and Lucence recently announced a collaboration to expand access to this cutting-edge cancer test that is designed to detect clinically relevant biomarkers in ctDNA and ctRNA.
During their conversation, Dr. Morice and Dr. Tan explore:
- Inspiration for developing the liquid biopsy.
- Features that differentiate LiquidHALLMARK® from existing cancer tests.
- Patients who will benefit from the test and how an oncologist might use the results.
- The future potential of liquid biopsy advancements.
More episodes from "Answers from the Lab"
Don't miss an episode of “Answers from the Lab” and subscribe to it in the GetPodcast app.